Icon Plc
ICLRICON plc (ICLR) is a global provider of outsourced clinical research services to the pharmaceutical, biotechnology, and medical device industries. The company specializes in conducting clinical trials, data management, and regulatory consulting, helping clients streamline the development and approval of new healthcare products. Established in Ireland, ICON has a broad international presence and is known for its expertise in efficient trial management and innovative solutions in the life sciences sector.
Company News
The global real world evidence (RWE) solutions market is projected to grow from $5.42 billion in 2025 to $10.83 billion by 2030, with a 14.8% CAGR, driven by value-based care, chronic disease prevalence, and advancements in healthcare data analytics.
Clinical research organization ICON reported better-than-expected Q2 financial results, with quarterly sales of $2.02 billion and adjusted earnings of $3.26 per share. The company raised its fiscal 2025 sales guidance and expanded its share buyback program to $1 billion.
The global regulatory affairs outsourcing market is expected to grow significantly from 2024 to 2030, driven by the globalization of biopharmaceutical and medical device companies and the need for specialized regulatory expertise. Technological advancements in regulatory processes are also shaping the market.
Faruqi & Faruqi, LLP is investigating potential claims against ICON plc for allegedly making false and/or misleading statements about its business and financial performance, leading to significant losses for investors.
Telix Pharmaceuticals Limited, a biopharmaceutical company, has appointed Anne Whitaker as a Non-Executive Director based in the United States. Whitaker is a seasoned healthcare leader with over 30 years of global corporate experience.
